Key result
STS-TR score overestimates early mortality after TTVI by ~3-fold and shows suboptimal discrimination.
Why the study?
The STS-TR score was developed to predict 30-day mortality after tricuspid valve surgery, but its performance in patients undergoing transcatheter tricuspid valve intervention needed evaluation.
Does the STS-TR surgical risk score accurately predict 30-day mortality in patients undergoing transcatheter tricuspid valve interventions?
Does the STS-TR surgical risk score accurately predict 30-day mortality in patients undergoing transcatheter tricuspid valve interventions?
The STS-TR surgical risk score significantly overestimates 30-day mortality and demonstrates suboptimal discrimination when applied to patients undergoing transcatheter tricuspid valve interventions, highlighting the need for dedicated TTVI risk models.
Answers are grounded in this paper and cite their sources.
STS-TR overestimation cautions against its use for TTVI decisions; challenges surgical score applicability and leaves open dedicated model development.
Background Transcatheter tricuspid valve intervention (TTVI) is increasingly utilized for symptomatic severe tricuspid regurgitation (TR), particularly in high-risk surgical patients. The Society of Thoracic Surgeons Tricuspid Regurgitation (STS-TR) score, that was developed for prediction of 30-day mortality after tricuspid valve surgery. The purpose of the current study is to evaluate the performance of the STS-TR score in patients who underwent TTVI. Methods A six-center international cohort of 457 patients who underwent TTVI for symptomatic severe or greater TR between 2019-2024 were assessed using the STS-TR score. TTVI included tricuspid edge-to-edge repair (T-TEER) (n=243), tricuspid valve replacement (TTVR) (n=131), and transcatheter tricuspid annuloplasty (TTA) (n=83). The STS-TR 30-day all-cause mortality score was calculated for each patient and compared to observed mortality. The performance of the STS-TR score was assessed using calibration plots, the Hosmer-Lemeshow (H-L) test, and C-statistic. Subgroup analyses were performed based on TTVI procedure type. Results Mean age was 78.6 ± 8.7 years, and 54.7% were female. The mean predicted 30-day all-cause STS-TR mortality was 8.16% ± 7.2%, while the observed mortality was 2.63% (p < 0.001). Subgroup analyses revealed similar calibration patterns, Figure 1. Calibration plots demonstrated overestimation across all procedure types. The C-statistic for the STS-TR score was 0.68 (95% CI: 0.54 - 0.82) (Figure 2), indicating suboptimal discrimination Conclusions The STS-TR score for isolated TR significantly overestimates TTVI 30-day mortality across all procedure types, including transcatheter repair (T-TEER and TTA) and replacement (TTVR), and demonstrates suboptimal discrimination. This may be related to lower risk of TTVI procedures compared to surgery or disparate cohorts. Prospective dedicated TTVI-specific risk prediction models for transcatheter repair and replacement procedures are needed.
No takes yet. Share an insight, caveat, or question.
Potratz et al. (2025) studied this question. The STS-TR score overestimated 30-day mortality after TTVI with suboptimal discrimination.
Synapse has enriched 10 related papers. Consider them for comparative context: